证券之星消息，1月12日医药商业板块较上一交易日上涨0.8%，润达医疗领涨。当日上证指数报收于 4165.29，上涨1.09%。深证成指报收于14366.91，上涨1.75%。医药商业板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 603108 | 润达医疗 | 19.47 | 8.53% | 109.56万 | | 21.23亿 | | 002462 | 嘉事堂 | 17.13 | 6.33% | 44.12万 | | 7.33亿 | | 300937 | 药易购 | 38.42 | 4.54% | 12.75万 | | 4.80亿 | | 603716 | 塞力医疗 | 29.09 | 4.53% | 68.90万 | | 19.36亿 | | 301408 | 华人健康 | 23.00 | 3.74% | 62.32万 | | 14.09亿 | | 002589 | 瑞康医药 | 3.48 | 3.26% | 99.63万 | | 3.44亿 | | ...

证券日报网讯1月7日，益丰药房（603939）发布公告称，公司本次为控股子公司石家庄新兴新增担保 58，500万元，累计对其担保余额升至95，000万元；截至公告日，公司及其控股子公司对外担保总额为 256，000万元，占最近一期经审计净资产23.87%，无逾期担保。 ...

| 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2026-002 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 关于为控股子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象 被担保人名称 石家庄新兴药房连锁有限公司（以下简 称"石家庄新兴"） 本次担保金额 58,500.00 万元 实际为其提供的担保余额 95,000.00 万元 是否在前期预计额度内 ☑是 □否 □不适用：_________ 本次担保是否有反担保 □是 ☑否 □不适用：_________ （二）内部决策程序 公司于 2025 年 4 月 28 日召开的第五届董事会第十六次会议与 2025 年 5 月 29 日召开的 2024 年年度股东会，审议通过了《关于为子公司申请银行授信提供 担保的议案》，石家庄新兴因经营发展需要，向银行申请授信额度，公司对其授 信进行担保，担保总额合计不超过 194,500.00 万元 ...

证券之星消息，1月6日医药商业板块较上一交易日上涨0.97%，鹭燕医药领涨。当日上证指数报收于 4083.67，上涨1.5%。深证成指报收于14022.55，上涨1.4%。医药商业板块个股涨跌见下表： | 代码 | 名称 | 主力净流入(元) | | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 002788 | 鹭燕医药 | - | 1.83 Z | 13.10% | -8072.97万 | -5.78% | -1.02 Z | -7.31% | | 002462 | 嘉事堂 | | 8495.89万 | 40.87% | -5184.99万 | -24.94% | -3310.90万 | -15.93% | | 603716 塞力医疗 | | | 3568.73万 | 19.33% | -1193.20万 | -6.46% | -2375.53万 | -12.87% | | 002589 | 瑞康医药 | | 2721.28万 | 9.02% ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | --- | | 603122 | 合富中国 | 23.13 | -5.20% | | 59.88万 | | 14.09亿 | | 002788 | 壁荷医药 | 20.65 | -2.50% | | 78.27万 | | 15.69 Z | | 600538 | 国发股份 | 6.08 | -0.65% | | 6.95万 | | 4249.54万 | | 600833 | 第一医药 | 13.00 | 0.54% | | 3.62万 | | 4715.90万 | | 601607 | XD上海医 | 17.85 | 0.62% | | 11.97万 | | 2.13亿 | | 603939 | 益丰药房 | 21.87 | 0.69% | | 8.60万 | | 1.88亿 | | 603233 | 大参林 | 17.76 | 0.79% | | 8.51万 | | 1.50亿 | | 603883 | 老百姓 | 14.93 | ...

未转股可转债情况：截至 2025 年 12 月 31 日，尚未转股的"益丰转债"面值 为人民币 1,797,249,000 元，占"益丰转债"发行总量的比例为 99.9898%。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 累计转股情况：截至 2025 年 12 月 31 日，累计已有面值 183,000 元"益丰转 债"转为公司 A 股普通股，累计转股股数为 5,571 股，占"益丰转债"转股前 公司已发行普通股股份总额的 0.0005%。 | 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2026-001 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 关于可转债转股结果暨股份变动公告 的"益丰转债"自2024年9月9日起可转换为公司股份。 本季度转股情况："益丰转债"自 2024 年 9 月 9 日起可转换为公司股份，2025 年 10 月 1 日至 2025 年 12 月 31 日共有面值 2, ...

Core Viewpoint - Yifeng Pharmacy has indicated that due to multiple factors such as the economic environment and industry cycles, the company will focus on improving operational quality, leading to a reduction in store openings and acquisition plans, resulting in a slowdown in revenue growth compared to previous periods [1] Group 1: Company Performance - For the period from January to September 2025, Yifeng Pharmacy achieved revenue of 17.286 billion yuan, representing a year-on-year growth of 0.39% [1] - The company reported a net profit attributable to shareholders of 1.225 billion yuan, which is a year-on-year increase of 10.27% [1] Group 2: Industry Outlook - The fundamental development logic of the industry remains unchanged, driven by factors such as accelerated population aging, medical reform separating medicine from medical services, and increased industry concentration [1] - Retail pharmacies are expected to continue to enhance their channel and social value as important entry points for community health [1] - The retail pharmacy industry is anticipated to experience new development opportunities with the ongoing innovation in diversified operations and the maturation of new retail models both online and offline [1]

Group 1 - The core investment theme for the pharmaceutical industry in 2025 is the overseas expansion of innovative drugs, which is expected to yield excess returns compared to the broader pharmaceutical sector and the CSI 300 index [2][21] - The innovative drug index has shown a significant increase, outperforming the pharmaceutical biological index by 37.48 percentage points, with a year-to-date increase of 65.99% [21] - Major transactions in the ADC and dual antibody fields are anticipated to continue, while there is a need to avoid repetitive competition in areas like small nucleic acids and focus on unmet clinical needs [3][4] Group 2 - The report emphasizes the importance of overseas markets for both innovative drugs and medical devices, suggesting that companies should seek growth opportunities beyond domestic market saturation [4][5] - The Chinese pharmaceutical industry is gradually becoming a global innovation center, with significant advancements in dual antibodies and ADCs, while also making strides in emerging fields like small nucleic acids and inhalation formulations [5][6] - The report highlights that the overseas authorization revenue has become a crucial funding source for innovative drug development, with a total upfront payment of $4.551 billion in the first three quarters of 2025 [29][32] Group 3 - The medical device sector is experiencing a shift towards overseas expansion, with a focus on high-value consumables and IVD products, as Chinese companies enhance their market share [7][55] - The export growth of high-value consumables is significant, with a recorded increase of 10.75% in the first half of 2025, particularly in the North American and European markets [57][66] - The report notes that the certification and market establishment processes for high-value consumables are long-term investments, requiring compliance with stringent regulations in the EU and the US [60][61] Group 4 - The recovery of financing in the domestic innovative drug sector has been robust, with a total of 324 financing events amounting to $5.51 billion in the first three quarters of 2025, marking a 67.6% increase year-on-year [70][72] - The CXO industry is experiencing varied recovery rhythms across different segments, with some areas like CDMO seeing order growth due to overseas financing recovery [74]

Market Overview - The pharmaceutical commercial sector declined by 0.69% on December 31, with Luyuan Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3968.84, up 0.09%, while the Shenzhen Component Index closed at 13525.02, down 0.58% [1] Stock Performance - Baiyang Pharmaceutical (301015) closed at 23.60, up 2.61% with a trading volume of 41,600 shares and a transaction value of 97.15 million [1] - Nanjing Pharmaceutical (600713) closed at 5.46, up 1.49% with a trading volume of 197,800 shares and a transaction value of 107 million [1] - Run Da Medical (603108) closed at 14.95, up 0.88% with a trading volume of 103,700 shares and a transaction value of 155 million [1] - Other notable stocks include Liuyuan Group (603368) at 17.82, up 0.62%, and China Pharmaceutical (600056) at 10.33, up 0.29% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 781 million from institutional investors, while retail investors saw a net inflow of 762 million [2] - The main capital inflow and outflow for selected stocks include: - Huaren Health (301408) with a net inflow of 83.36 million from institutional investors [3] - Shanghai Pharmaceutical (601607) with a net inflow of 22.40 million from institutional investors [3] - Yifeng Pharmacy (603939) with a net inflow of 19.37 million from institutional investors [3]

Investment Rating - The report suggests a positive investment outlook for the medical device sector, particularly in brain-computer interface devices, which are expected to see accelerated commercialization due to supportive policies [1][3]. Core Insights - Recent policies have significantly increased support for innovation in medical devices, with the National Medical Products Administration actively promoting faster market entry for brain-computer interface devices, indicating a diverse application landscape and substantial future potential [1][3]. - The pharmaceutical sector is witnessing positive developments, such as GSK's approval of mepolizumab for a new indication in COPD patients, marking it as the first monthly administered biologic in China, which is expected to reduce the annual incidence of severe exacerbations significantly [1][32]. - The report highlights the approval of Wegovy® tablets in the U.S. for weight management, emphasizing its potential impact on the market as the first oral GLP-1 receptor agonist for this purpose [37][40]. Summary by Sections Pharmaceutical Sector - Mepolizumab has been approved for COPD treatment in China, with a monthly dosing schedule, targeting a significant patient population [1][32]. - The A/H share innovation drug sector maintains high activity levels, with new drug approvals and cross-border transactions remaining robust [16][28]. Biologics - Wegovy® tablets have been approved in the U.S. for weight management, showing similar weight loss efficacy to its injectable counterpart, with a significant portion of participants achieving substantial weight loss [37][40]. CXO and Pharmaceutical Supply Chain - The CXO sector continues to show upward momentum, supported by a stable order backlog, with November financing levels slightly above the annual average [44][46]. Medical Devices - The centralized procurement process for high-value medical consumables is progressing steadily, with high selection rates in multiple rounds of bidding, indicating a favorable environment for leading domestic companies [2][52]. Retail Pharmacy - The industry is undergoing a consolidation phase, with leading companies expected to benefit from increased market share through mergers and acquisitions [2][3]. Medical Services and Consumer Healthcare - Aier Eye Hospital's acquisition of 39 institutions for 960 million yuan strengthens its market position, with the acquired entities showing signs of financial recovery [2][3].